Skip to main content
Premium Trial:

Request an Annual Quote

Genizon, Speid Partner on Predictive Drug Technology

NEW YORK (GenomeWeb News) – Genizon BioSciences has entered into a partnership with drug development consultancy Speid & Associates to offer that firm's clients access to Genizon's predictive techniques in the drug development process.

Speid's customers will use Genizon's genetic platform to identify and eliminate compounds that have a relatively low chance of success early in the drug development cycle.

"The combination of Genizon's proprietary gene discovery platform and Speid's expertise in regulatory affairs will assure expeditious pathways to commercialization," Genizon CSO and Founder Majid Belouchi, said in a statement.

Financial and other terms of the pact were not disclosed.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.